Generic Name and Formulations:
Dapsone 5%; gel.
Indications for ACZONE:
Wash skin and pat dry. Apply pea-sized amount to affected area in a thin layer twice daily in the AM & PM. Rub in gently and completely. Wash hands after use. Reevaluate if no improvement after 12 weeks.
Avoid in congenital or idiopathic methemoglobinemia. G6PD deficiency: may have increased risk of methemoglobinemia or hemolytic anemia; discontinue if occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.
Increased risk of hemolysis in G6PD-deficient patients with concomitant trimethoprim/sulfamethoxazole, other folic acid antagonists (eg, pyrimethamine), anticonvulsants, rifampin, St. John's wort. Increased risk of methemoglobinemia with concomitant sulfonamides, acetaminophen, chloroquine, nitrates, nitrites, nitrofurantoin, phenobarbital, phenytoin, primaquine, quinine, and others. Skin/hair discoloration with topical benzoyl peroxide.
Application site reactions (oiliness, peeling, dryness, erythema, pruritus).
Gel 5% (tubes)—60g, 90g; Gel 7.5% (pumps)—30g, 60g, 90g
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies